Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Inclusion Criteria: Histologically or cytologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer Recurrent or metastatic disease Measurable disease, defined as ≥ 1 unidimensionally measurable indicator lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan Must have received a platinum-containing chemotherapy regimen for primary disease Re-treatment with a platinum-based regimen required for patients who achieved a clinical complete response (CR) to primary therapy and then had a treatment-free interval > 12 months (i.e., platinum-sensitive) unless the patient developed a hypersensitivity to platinum Patients with a treatment-free interval < 12 months do not require prior chemotherapy for recurrent disease No evidence of CNS disease, including primary brain tumors or brain metastasis Performance status - ECOG 0-2 More than 3 months WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No history of bleeding diathesis SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastasis) Bilirubin normal INR ≤ 1.5 (3 if receiving warfarin) No history of esophageal varices Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 60 mL/min Urine protein < 1+ Urine protein < 1,000 mg on 24-hour urine collection Urine protein:creatinine ratio < 1.0 No arterial thromboembolic event within the past 6 months, including any of the following: Transient ischemic attack Cerebrovascular accident Unstable angina pectoris Myocardial infarction No clinically significant peripheral artery disease No uncontrolled hypertension No New York Heart Association grade II-IV congestive heart failure No serious cardiac arrhythmia requiring medication No peripheral vascular disease ≥ grade 2 Not pregnant No nursing during and for ≥ 3 months after study participation Negative pregnancy test Fertile patients must use effective contraception during and for ≥ 3 months after study participation No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs (e.g., Chinese hamster ovary cell products or recombinant humanized antibodies) No serious or non-healing wound, ulcer, or bone fracture No active infection requiring parenteral antibiotics No other active malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix No gastrointestinal tract disease resulting in an inability to take oral medication No significant traumatic injury within the past 28 days No known HIV positivity No prior bevacizumab See Disease Characteristics No more than 2 prior cytotoxic chemotherapy regimens for recurrent or refractory disease (i.e., failed to achieve a clinical CR after primary therapy) More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) More than 4 weeks since prior radiotherapy No prior radiotherapy to any indicator lesion unless disease has progressed since completion of radiotherapy More than 4 weeks since prior major surgical procedure or open biopsy More than 1 week since prior core biopsy No prior surgery affecting absorption No concurrent major surgery Recovered from prior therapy No prior vascular endothelial growth factor (VEGF) or an epidermal growth factor receptor (EGFR) directed therapy No prior erlotinib At least 30 days since prior investigational drugs More than 1 month since prior thrombolytic agents Concurrent warfarin allowed provided the following criteria are met: Patient is on a therapeutic stable dose of warfarin INR ≤ 3 No active bleeding or pathological condition that would confer a high risk of bleeding (e.g., tumor invading adjacent organs or major blood vessels or varices that are likely to bleed) No other concurrent investigational agents No other concurrent anticancer therapy